Abstract 219P
Background
Retrospective investigations indicate that inhibiting PI3Kδ and/or γ, which are prevalent in leukocytes, elicits an anticancer immune response by reducing the activity of immunosuppressive cells. However, the isolated inhibition of either PI3Kδ or γ is insufficient for the complete eradication of solid tumors.
Methods
We utilized BR101801, a PI3Kδ/γ inhibitor, in the CT-26 syngeneic mouse model with a subcutaneously implanted tumor. BR101801 was delivered on a daily basis, and the target tumor region received localized irradiation. We consistently observed tumor growth and assessed immunological alterations via flow cytometry, ELISpot, and transcriptional analysis. Furthermore, we examined the mechanism of anticancer immunological effects via BR drug and radiation therapy by inhibiting the pathway using antibody treatment.
Results
Together with irradiation, BR101801 reduced Treg proliferation and increased tumor-specific CD8α+ T cells in the tumor microenvironment, leading to tumor regression. Post-irradiation, the CD8α+ T cell to Treg ratio increased for 14 days, causing remote tumor regression in metastatic lesions, known as the abscopal effect. Combining BR101801 with irradiation enhances the immune-stimulatory tumor microenvironment, transforming immunologically cold tumors into hot ones, according to transcriptome analysis. Additionally, we examined CD8 T cell recruiting cells and methods. Previous studies on Batf3, which is involved in IFN-related genes and cross-presentation in cancer, were confirmed. We checked if IFNAR1 antibody administration negated the combined treatment's anticancer activity, and the result showed that only the monotherapy's effect was seen. The previously established CD8 T cell infiltration did not occur, and PMN-MDSC's immunosuppressive impact was eliminated.
Conclusions
Preclinical data indicates that PI3Kδ/γ suppression and irradiation can enhance systemic antitumor immunity against solid tumors, suggesting its potential as an immune-regulatory radiosensitizer.
Legal entity responsible for the study
Boryong Co.
Funding
Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by the Ministry of Science and ICT (MSIT), The Republic of Korea (No. 50531-2021), and the National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract